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The technique of 32P postlabeling of DNA-carcinogen adducts is a useful and extremely sensi- 
tive method of detecting and quantitating DNA damage by carcinogens. We have adapted the 
32P method to analysis by high-pressure liquid chromatography, making the procedure more 
rapid and convenient than when thin-layer chromatography is used. Following DNA isolation 
and hydrolysis, nucleotide-carcinogen adducts are enhanced relative to normal nucleotides by 
solvent extraction and then labeled with high-specific-activity [T-~~P]ATP. The resulting 32P- 
postlabeled nucleotides are resolved by reverse-phase ion-pair HPLC. After as little as 3 h of 
exposure to carcinogens, DNA adducts can be demonstrated from 1 pg or less of mouse hepatic 
DNA. Acetylated and nonacetylated adducts can be resolved from hepatic DNA of mice treated 
with 2-aminofluorene. Differences in DNA damage as measured by adduct formation were dem- 
onstrated between “rapid” and “slow” acetylator mouse strains. Rapid-acetylator C57BL/6J 
mice had three times the amount of hepatic DNA adducts as slow-acetylator A/J mice 3 h after 
a 60 mg/kg dose of 2-aminofluorene. 4-Aminobiphenyl and 2-naphthylamine each showed an 
adduct peak with retention time similar to that of the nonacetylated 2-aminofluorene adduct, 
while benzidine gave a major adduct that eluted somewhat earlier as would be expected for an 
acetylated adduct. The alkenylbenzenes, safrole and methyleugenol, also formed DNA adducts 
detectable by this method. DNA prepared from skin of mice painted with benzo[a]pyrene also 
contained carcinogen-DNA adducts detectable and resolvable by HPLC analysis following 32P 
postlabeling. The combination of HPLC with “P postlabeling appears to be a useful technique 
for the rapid detection and quantitation of DNA damage caused by several classes of aromatic 
carcinogens. 0 1988 Academic F’ress, Inc. 
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The formation of a covalent adduct be- 
tween a carcinogen/mutagen and a DNA nu- 
cleotide is generally considered a crucial step 
in a common mechanism of carcinogenesis/ 
mutagenesis. Detection and quantitation of 
such a complex require extremely sensitive 
methods as the level of adducted nucleotides 
may be only 1 in lo6 to 1 in lo9 or less normal 
’ This research was supported by USPHS Grants CA- 
390 18 and GM-27028. Brief preliminary accounts of this 
work have been presented at the 26th Annual Meeting 
of the Society of Toxicology, Washington, DC, February 
1987, and the Third International Conference on Carci- 
nogenic and Mutagenic N-Substituted Aryl Compounds, 
Dearborn, MI, April 1987. 
nucleotides. The introduction of “P postla- 
beling of adducted nucleotides by Randerath 
et al. (1) and Gupta et al. (2) is proving to be 
a useful addition to the methods of detecting 
adducts. The advantages of 32P postlabeling 
compared with other sensitive methods in- 
clude the wide applicability of the method to 
adducts formed from many aromatic and 
nonaromatic carcinogens (3), the elimination 
of radiolabeled carcinogens which may be ex- 
pensive, in need of custom synthesis, or of 
unacceptably low specific activity, and the 
absence of the need to produce antibodies as 
required in immunological methods. 
The clear advantage of 32P postlabeling as 
a screening method for carcinogens is some- 
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what mitigated by the need to separate the ad- 
ducts by multiple-solvent thin-layer chroma- 
tography (TLC) and detect the results by au- 
toradiography. Quantitation is then carried 
out by cutting out the radioactive areas or 
scraping the plates and scintillation counting. 
These procedures are time consuming and 
must be done with great care and precision to 
achieve reproducible results. 
We have adapted the detection and quanti- 
tation aspects of 32P postlabeling to HPLC. 
Postlabeled nucleotide adducts are separated 
from normal nucleotides, ATP, Pi, and other 
components by reverse-phase ion-pair HPLC 
using a gradient of acetonitrile in phosphate 
buffer containing ion-pairing reagent. This 
method has been extremely reproducible, de- 
tects a variety of carcinogen-DNA adducts, 
and requires about 60 min from 32P labeling 
to results. In experiments with radiolabeled 
carcinogen, it was found that the HPLC 
method is useful with nucleotide 3’-phos- 
phates as well as with the nucleotide 3’,5’-di- 
phosphates. The method we describe is useful 
not only in determining if the aromatic car- 
cinogens have formed covalent DNA ad- 
ducts, but also in partially resolving various 
adducts from one another and quantitating 
total adduct formation. We include data on 
the use of HPLC analysis of 32P-postlabeled 
DNA-2-aminofluorene adducts from two in- 
bred mouse strains which demonstrate 
differences in their ability to N-acetylate aro- 
matic amines. 
MATERIALS AND METHODS 
Animals and chemicals. Mice (C57BL/6J 
and A/J) were purchased from Jackson Labo- 
ratories, Bar Harbor, Maine. Polynucleotide 
kinase, 3’-phosphatase free, was from Boeh- 
ringer-Mannheim Biochemicals, Indianapo- 
lis, Indiana. Tetrabutylammonium phos- 
phate, tetramethylammonium chloride, 4- 
ABP,2 safrole, and methyleugenol were from 
’ Abbreviations used: 2-AF, 2-aminofluorene; 2- 
NA, 2naphthylamine; 4-ABP, 4-aminobiphenyl; AAF, 
Aldrich Chemical Company, Milwaukee, 
Wisconsin. 3’S’-Diphosphates of deoxy- 
nucleotides were from Pharmacia P-L Bio- 
chemicals, Piscataway, New Jersey. N-Ace- 
toxy-AAF was from the NC1 Chemical 
Carcinogen Repository, N-acetoxy-Zacetyl- 
amino-[ring-G-3H]fluorene was from Chem- 
syn Science Labs, Lenexa, Kansas. dG-C8- 
AF-3’-phosphate was a gift from Dr. Charles 
King and Tom Reid, Michigan Cancer Foun- 
dation, Detroit, Michigan. [T-~~P]ATP was 
from Amersham, Arlington Heights, Illinois. 
Acetonitrile was Fisher HPLC grade. Prote- 
ase K, spleen phosphodiesterase II, micrococ- 
cal nuclease, nuclease Pl, RNase’s, apyrase, 
2-AF, 2-NA, benzidine, and ATP were from 
Sigma Chemical Company, St. Louis, Mis- 
souri. Benzo[a]pyrene-adducted mouse skin 
DNA was a gift from Dr. David Springer, Bat- 
telle Laboratories, Richland, Washington. 
Isolation of DNA. Hepatic DNA was pre- 
pared by homogenization of fresh or frozen 
liver in 50 mM Tris, 25 mM KCl, 5 mM 
MgC12, 250 mM sucrose, pH 7.5. The homog- 
enate was added to an equal volume of 1 M 
NaCl, 0.1 M EDTA, 2% SDS, pH 8, at 60°C 
and maintained at this temperature for 15 
min. The lysate was cooled to 37°C and incu- 
bated with 0.5 mg/ml proteinase K for 60 
min. The DNA was extracted sequentially 
with 1 vol phenol, 1 vol phenol/chloroform/ 
isoamyl alcohol (25:24:1), and 1 vol chloro- 
form/isoamyl alcohol (24: 1). After ethanol 
precipitation, the DNA was redissolved in 10 
ITIM Tris, 1 mM EDTA (pH 7.5). DNA was 
further treated with RNase A ( 100 pg/ml) and 
RNase T 1 (50 U/ml) at 37°C for 30 min, fol- 
lowed by addition of SDS to 0.5% and 0.5 
mg/ml proteinase K and incubation for a fur- 
2-acetylaminofluorene; dG, deoxyguanosine; dG-C8- 
AAF, N-acetyl-N-(deoxyguanosin-8-yl)-2-aminofluor- 
ene or its 3’,5’-diphosphate; dG-C8-ABP, N-(deoxygua- 
nosin-8-yl)-4-aminobiphenyl; dG-C8-AF, N-(deoxygua- 
nosin-8-yl)-2-aminofluorene or its 3’Jdiphosphate; 
N-acetoxy-AAF and N-[3H]acetoxy-AAF, N-acetoxy-2- 
acetylaminofluorene and ring-labeled N-[‘Hlacetoxy-2- 
acetylaminofluorene; pdGp, deoxyguanosine 3’,5’-di- 
phosphate; TBAP, tetrabutylammonium phosphate. 
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TABLE 1 
CARCINOGENS TESTED 
stance tested a control injected with solvent 













330 DMSO” 16 
860 Tricap’ 3 
350 DMSO 2 
315 DMSO 2 
600 Tricap 2 
2000 Tricap 2 
To study the effect of differing N-acetyl- 
transferase activity on adduct formation, in- 
bred C57BL/6J (B6) and A/J (A) mice were 
injected ip with 2-AF in DMSO (60 mg/kg). 
At 3 h, the mice were sacrificed and hepatic 
DNA was prepared as described. In each ex- 
periment a littermate was dosed with DMSO 
only and used as a control for adduct deter- 
mination. 
a Dimethyl sulfoxide. 
b Tricaprylin. 
ther 30 min. This was followed by two extrac- 
tions with chloroform/isoamyl alcohol (24: 
1). After precipitation with ethanol, the DNA 
was dissolved in succinate buffer (20 mM Na 
succinate, 10 IIIM CaC&, pH 6). Quantitation 
of DNA was by absorbance at 260 nm. 
Hydrolysis of DNA. Hydrolysis was a mod- 
ification of the method of Gupta et al. (2). In 
most experiments 2-5 pg DNA was digested 
in succinate buffer (pH 6) containing 10 mM 
CaC12 with 0.05 U spleen phosphodiesterase 
II and 2.25 U micrococcal nuclease in 20 ~1 
total volume for 3 h at 37°C. 
In vitro modification of DNA and prepara- 
tion of adduct standards. Hepatic DNA was 
treated with N-acetoxy-AAF (2 mM) in 10 
mM Na citrate, pH 7, 30% ethanol as de- 
scribed by Gupta et al. (2). Repeated extrac- 
tion with diethyl ether was used to remove 
unbound carcinogen. The modified DNA 
was precipitated with ethanol. 
Enrichment of adducts. A modification of 
the butanol extraction procedure of Gupta 
(4) was used. To 20 ~1 DNA hydrolysis reac- 
tion were added 25 ~1 100 mM ammonium 
formate pH 3, 15 ~1 50 mrvt tetrabutylam- 
monium chloride, and 10 ~1 water. This was 
extracted twice with 70 ~1 I-butanol (water 
saturated) and the combined extracts were 
back-extracted with 125 ~1 water (butanol 
saturated). After addition of 3 ~1 of 200 mM 
Tris, pH 9.5, to the final butanol extract, the 
extract was dried using a Speed-Vat. 
A similar procedure was used with 50 ~1 of 
N-[3H]acetoxy-AAF (938 mCi/mmol, I .45 
mCi/ml) and 142 pg DNA. 
The acetylaminofluorene adduct of deoxy- 
guanosine 3’,5’-diphosphate was prepared as 
above using 15 mM pdGp and 10 mM N-acet- 
oxy-AAF in 200 ~1 of 5 mM Na acetate, pH 
4.8, 50% ethanol as described by Gupta 
et al. (2). 
The acetylated aminofluorene adduct of 
deoxyguanosine 3’-phosphate was similarly 
prepared. 
32P labeling of nucleotides. The dried prep- 
aration of butanol-extracted nucleotides was 
redissolved in 15 ~1 water and labeled with 5 
~1 of a labeling mix. The mix was prepared so 
that each 5 ~1 contained 2.5 ~1 10X buffer (0.1 
M Bicine, 0.1 M MgCl2,O. 1 M dithiothreitol, 
0.01 M spermidine, pH 9), 7 U polynucleo- 
tide kinase, and 20-25 &i [T-~~P]ATP 
(5000-6000 Ci/mmol). The kinase reaction 
was run at 37°C for 35 min. Approximately 
100 mU apyrase (4 ~1) was added and incuba- 
tion continued 30 min. 
In vivo modljication of DNA. Mouse he- HPLC. A Varian 5060 ternary liquid chro- 
patic DNA was prepared from individual matograph equipped with a UV- 100 detector 
C57BL/6J inbred mice injected ip with car- was used. The column was an Ultrasphere 
cinogens in the doses and solvents shown in ion pair Cl8 4.6 X 250 mm with a 70-mm 
Table 1. The volume injected was IOO- 150 guard column of octadecylsilane. UV detec- 
~1. The exposure time was 3 h. For each sub- tion was at 254 nm. For radioactivity deter- 
minations, fractions (1.5 ml) were collected duct levels (Fig. 1). The adduct peak (dG-C8- 
in plastic minivials using a Helirac fraction AAF) elutes at 36 min with gradient I or II 
collector. For tritium-labeled samples, radio- (Fig. 1). Use of gradient I results in a lower 
activity was determined using 0.5-ml aliquots level of background radioactivity in the vicin- 
of column fractions in 5 ml of Safety-Solve ity of the adduct (higher signal-to-noise ratio) 
(Research Products International, Elk Grove when using 32P-labeled samples. 
Village, IL). Radioactivity of 32P-labeled sam- The choice of ion-pairing agent is crucial to 
ples was determined by Cerenkov counting. the separation. When tetramethylammo- 
An LKB 1218 Rackbeta scintillation spec- nium salt was substituted for tetrabutylam- 
trometer was used. monium, the dG-C8-AAF standard eluted at 
Radiolabeled samples or standards were 2 1 min rather than 36 min (Fig. 2). This ear- 
combined with unlabeled adduct standard lier elution was unacceptable as nonadduct 
and injected into the HPLC via a Rheodyne 32P from the labeling mixture was not ade- 
7 125 injector using a 50- or loo-p1 loop. La- quately eluted from the column before the 
beled nucleotides from between 1 and 3 pg of adduct eluted. 
DNA ( 10 ~1 of a 24-~1 labeling reaction) were 
injected in a total volume of 50 ~1. Gradient HPLC Separation of 3H-Labeled 
I had initial conditions of flow 1.5 ml/min, Aminojluorene Adducts 
90% 30 mM KP04 (pH 6), 10% CH3CN for 
10 min followed by 90% 30 mM KP04 (pH 6) dG-C8-[3H]AAF prepared by reacting 
containing 5 mM TBAP, 10% CH,CN in- mouse hepatic DNA with tritium-labeled N- 
creasing linearly to 50% at 50 min. This gradi- acetoxy-AAF at pH 5 eluted as a single major 
ent was used to separate adducted nucleo- radioactive peak at 37 min (gradient I). This 
tides from normal nucleotides, Pi, and resid- coincided with the uv detection of dG-CS- 
ual ATP. The column was prepared for the AAF (Fig. 3). 
next sample by a 1 0-min wash at 20/80 phos- The 3’-monophosphate of dG-C8-AAF 
phate-TBAP:CH$ZN and reequilibrated at eluted 2-3 min earlier than the 3’,5’-diphos- 
the starting conditions. The loop and syringe phate, while the Y-monophosphate of dG- 
used for sample injection were rinsed be- C8-AF eluted at nearly the same position as 
tween uses. There was no evidence of con- 
the diphosphate of the acetylated adduct. 
tamination between samples. HPLC Detection of 2-AF Adducts Formed 
in Vivo 
RESULTS Hepatic DNA from mice exposed to 2-AF 
HPLC Separation of Nucleotide Standards was prepared, hydrolyzed, extracted, 32P- 
postlabeled, and analyzed by HPLC. With 
Gradient I allowed a clean separation of gradient I, two peaks of 32P were detected: 
adducted nucleotides from normal nucleo- fraction 36 and fractions 40-42. The uv stan- 
tides, Pi, and residual ATP. If conditions dard eluted between 36 and 37 min. Frac- 
were modified by having 5 mM TBAP in the tions 36 and 37 accounted for approximately 
eluting buffer from the start (gradient II), all 20% and fractions 40-42 for 80% of adduct 
four normal nucleotides as well as ATP and 32P radioactivity. 
nucleotide-carcinogen adducts could be sep- Control DNA was always run under identi- 
arated. However, counts of 32P, presumably cal labeling and HPLC conditions. Figure 4A 
from impurities in the [T-~~P]ATP, were still shows the elution profile of a control B6 
eluting from the column when AF adducts mouse, whereas Fig. 4B shows the pattern of 
began to elute. Thus, gradient I was used to elution for 2-AF in hepatic DNA from a 
avoid interference in the quantitation of ad- treated B6 mouse. Figure 4C shows the 
384 LEVY AND WEBER 
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A. 
TIME (MIN) TIME (MIN) 
FIG. 1. HPLC separation of 3’,5’-diphosphates of deoxycytidine, deoxyguanosine, thymidine, and deoxy- 
adenosine (l-4), ATP (5), and dG-WAAF-3’,5’-diphosphate (6). Detection by uv absorbance at 254 nm. 
(A) Gradient II; retention times were 13.8, 15.2, 17.4, 19.4,27.4, and 36.1 min. (B) Gradient I; retention 
time ofdG-C8-AAF-3’,5’-diphosphate was 35.9 min. 
difference between treated and control he- The amount of adduct found is calculated 




37 and 40-42, the efficiency of counting, the 
B. 
TIME (FAN) 
FIG. 2. Effect of chain length of ion-pairing agent on adduct retention time. dG-C8-AAF-3’,5’-diphos- 
phate was run using Gradient I. (A) Gradient contained tetrabutylammonium salt. (B) Gradient contained 
tetramethylammonium salt. 
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FIG. 3. HPLC profile of dG-C8-‘H-AAF-3’,5’-diphos- 
phate ‘H-labeled adduct standard was prepared from N- 
[‘Hlacetoxy-AAF and mouse hepatic DNA. Adducted 
DNA was hydrolyzed, phosphorylated with ATP and 
polynucleotide kinase, and run on HPLC using gradient 
I. Aliquots of each fraction were added to scintillation 
cocktail and counted for ‘H. The arrow in this and subse- 
quent figures shows the retention of the internal standard 
of dG-C8-AAF-3’,5’diphosphate as detected by its absor- 
bance at 254 nm. 
specific activity of the [T-~~P]ATP used in the 
labeling, and the sample size of DNA nucleo- 
tides analyzed. Results from 11 B6 and 5 A 
A. C57BU6J Control 
mice gave values of 0.327 + 0.058 (SE) pmol 
adduct/mg DNA for B6 and 0.106 + 0.0 19 
pmol adduct/mg DNA for A mice. The inter- 
strain difference is statistically significant at 
P<O.Ol. 
HPLC Detection of DNA 32P-Postlabeled 
Adducts of Benzo[a]pyrene, 4- 
Aminobiphenyl, 2-Naphthylamine, 
Benzidine, Safrole, and Methyleugenol 
Skin DNA from mice treated with 
benzo[a]pyrene and hepatic DNA from mice 
treated with 4-aminobiphenyl, 2-naphthyl- 
amine, benzidine, safrole, and methyleu- 
genol were subjected to the HPLC/32P-postla- 
beling procedure. For each substance, control 
DNA from a mouse dosed with solvent only 
was analyzed and radioactivity in the control 
was subtracted from the 32P found in the 
treated DNA. In all cases, peaks of 32P radio- 
activity were found in the region of the chro- 
matogram near where 2-AF adducts eluted. 
B. C57BLl6J Treated 
'"""II I 
Fncffon (min) 
C. 2-Aminofluorene in C57BLGJ 
FIG. 4. HPLC analysis of 3zP-postlabeled C57BL/6J mouse hepatic DNA using gradient I. (A) Control- 
mouse treated with solvent (dimethyl sulfoxide) only. (B) Treated-mouse after 3 h exposure to 2-AF. (C) 
Hepatic DNA from 2-AF-treated mouse less control. For both treated and control DNA, fraction 2 had 
the greatest radioactivity with approximately 6.2 X lo6 cpm. 
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The amounts of radioactivity varied consid- 
erably from one carcinogen to another partly 
because of inherent differences in carcinogen 
binding indices and partly because different 
amounts of DNA were analyzed, different 
concentrations and specific activities of [y- 
32P]ATP were used, and probably various nu- 
cleotide adducts behave differently in the 
steps of the method. Examples of chromato- 
grams are shown in Fig. 5. These examples 
show the qualitative detection of DNA-aro- 
matic carcinogen adducts. Due to variations 
in the amounts of DNA, carcinogen, and 
ATP used, no quantitative comparisons 
should be made from the results shown in 
Fig. 5. 
DISCUSSION 
The method of 32P-postlabeling DNA-car- 
cinogen adducts developed by Randerath 
and Gupta et al. (1,2) is sensitive, fairly rapid, 
and applicable to adducts of a wide range of 
aromatic or bulky carcinogens. We have re- 
placed the thin-layer chromatographic sepa- 
ration of 32P-labeled adducted nucleotides 
with high-performance liquid chromatogra- 
phy. Our procedure, like the TLC method of 
Reddy et al. (3), can be applied to a range of 
aromatic compounds, some of which are de- 
scribed in this report. Likewise, a complex 
mixture of potential carcinogens can be ana- 
lyzed for adduct formation without a detailed 
knowledge of the chemical identity of the 
compounds (e.g., coal liquification products, 
data not shown). 
Since the Randerath procedure uses ion- 
exchange thin-layer materials, we originally 
thought that ion-exchange HPLC would be 
useful in separating normal and adducted nu- 
cleotides. Although normal nucleotides were 
adequately resolved by ion-exchange HPLC, 
modified nucleotides were not clearly distin- 
guishable. The affinity of aromatic DNA ad- 
ducts for reverse-phase chromatography ma- 
terials (5) suggested that reverse-phase HPLC 
might give the desired resolution. Reddy et al. 
(3) had used reverse-phase TLC as a purifica- 
tion step in TLC analysis of 32P-postlabeled 
aromatic adducts. To cleanly separate nor- 
mal from aromatic nucleotides, we modified 
the reverse-phase ion-pairing HPLC method 
of Payne and Ames (6) for separation of nu- 
cleotides. The gradient elution described in 
our report elutes normal nucleotides and ma- 
terial from the ATP labeling in a single early 
peak, washes background 32P from the col- 
umn, and resolves 2-AF adducts into two sep- 
arate peaks which presumably correspond to 
dG-C8-AAF and dG-C8-AF (Fig. 4). 
We have been able to identify the peak with 
a retention time of 36-37 min as N-acetyl-N- 
(deoxyguanosin-8-yl)-2-aminofluorene-3’,5’- 
diphosphate by use of standards prepared by 
reacting N- acetoxy - 2 - acetylaminofluorene 
with pdGp, or with deoxyguanosine 3’-phos- 
phate followed by phosphorylation at the 5’ 
position. Standard dG-CS-AAF was also pre- 
pared by hydrolysis and phosphorylation of 
DNA that had been reacted with N-acetoxy- 
2-AAF. In vitro incubation of N-[3H]acetoxy- 
AAF with isolated DNA gave only a single ra- 
dioactive peak, coeluting with uv standard of 
the nucleotide 3’,5’-diphosphate of dG-C8- 
AAF (Fig. 3). 
The peak eluting at 40-43 min contained 
about 80% of the total adduct radioactivity. 
We tentatively identify this later peak as the 
nonacetylated nucleotide adduct dG-C8-AF. 
The basis for this assumption is that previous 
studies have shown the major hepatic DNA 
adduct formed after 2-AF exposure to be dG- 
C8-AF (2,7). The later eluting peak is found 
after in vivo exposure to 2-AF but not after in 
vitro incubation with N-acetoxy-2-AAF. This 
is to be expected from the known pathways of 
metabolic activation of 2-AF which include 
formation of N-acetoxy-2-aminofluorene by 
either direct O-acetylation or N, 0-acetyl 
transfer followed by removal of the acetoxy 
group to give an electrophilic arylnitrenium 
ion capable of combining covalently with 
DNA to give the dG-C8-AF adduct (8). The 
formation of a labile N-acetoxy-2-aminoflu- 
orene intermediate occurs only through met- 
abolic activation. Since we found the putative 
388 LEVY AND WEBER 






25 30 35 40 45 50 
Fraction (min) 
C. 2-Naphthylamine --t Contro, 
- Treated 
E. Safrole - Control 
1500 1 
- Treated 
o-l....+--.,. . ..I..........1 













0+---r-..,. . ..r.....- 
25 30 35 40 45 SO 
Fraction fmin) 
FIG. 5. (A) HPLC analysis of “P-postlabeled skin DNA from benzo[a]pyrene-treated mouse and control 
mouse skin DNA (ATP specific activity = 4500 Ci/mmol). (B-F) Each chromatogram shows HPLC anaiy- 
sis of 32P-postlabekd hepatic DNA of treated mouse and the matching control. (B) 4-ABP (ATP specific 
activity = 4500 Ci/mmol). (C) 2-NA (ATP specific activity = 5500 Ci/mmol). (D) Benzidine (ATP specific 
activity = 4500 Ci/mmol). (E) Safrole (ATP specific activity = 4500 Ci/mmol). (F) Methyleugenol (ATP 
specific activity = 1750 Ci/mmol). 
dG-C8-AF adduct only following in vivo ex- tion time of the second 2-AF nucleotide 3’,5’- 
periments and under conditions known to diphosphate adduct peak (3-5 min) com- 
produce mainly dG-CS-AF, we provisionally pared to the acetylated nucleotide adduct is 
identify the adduct peak at 40-43 min as dG- the same increase seen between standards of 
Cg-AF. Furthermore, the increase in reten- nucleosides of dG-C8-AAF and dG-C8-AF 
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when run on gradient I (data not shown). De- 
finitive identification of the second adduct 
peak awaits synthesis of the proper standard. 
The reverse-phase ion-pair HPLC separa- 
tion appears to depend on the affinity of the 
aromatic moiety of the adduct for the C 18 re- 
verse-phase column material. Thus, the ad- 
ducts are bound to the column matrix while 
normal nucleotides and other charged mole- 
cules are removed. In the presence of the ion- 
pairing agent (added after 10 min in gradient 
I) the aromatic adduct-nucleotide-tributyl- 
ammonium complex is eluted by increasing 
concentrations of acetonitrile. Since several 
diverse adducts elute at a fairly similar aceto- 
nitrile concentration, the structure of the car- 
cinogen is not the only determinant of elu- 
tion position. The evidence suggests that the 
number of phosphates and thereby the num- 
ber of tetrabutylammonium groups play a 
significant part in determining the elution po- 
sition of adducts (e.g., the earlier elution of 3’- 
monophosphate compared to 3’,5’-diphos- 
phate of dG-C8-AAF). The importance of 
the chain length of the ion-pairing agent 
is demonstrated by the dramatic decrease 
in retention of dG-C8-AAF-3’S’-diphosphate 
when tetramethylammonium is substituted 
for tetrabutylammonium (Fig. 2). The find- 
ing of a second, later eluting peak of 32P-la- 
beled adduct (presumably C8-dG-AF) when 
DNA is modified in vivo by 2-AF but not 
when N-acetoxy-AAF is reacted with DNA in 
vitro (compare Fig. 4 with Fig. 3) suggests that 
an acetyl group can influence the retention of 
adducts on the column. 
Two additional comments on the 32P-past- 
labeling method are worthy of mention. A 
sample of control DNA from an animal of 
identical genetic and environmental back- 
ground should be run parallel to that for the 
carcinogen-treated animal. This is because 
32P spots (I-sp ots have been found in un- ) 
treated DNA from various tissues (9). The or- 
igin of these spots has been ascribed to envi- 
ronmental factors such as diet or to endoge- 
nous DNA-reactive metabolites. The amount 
and intensity of I-spots appears to increase 
with the age of the animal. Control hepatic 
DNA run in the HPLC/32P-postlabeling 
method shows 32P in the area of the chroma- 
togram where adducted nucleotides elute. Al- 
though such radioactivity is significantly less 
than that found in the carcinogen-treated 
DNA, it can be confusing when working with 
low adduct levels or unknown compounds. 
Any attempts to quantitate adducts must 
take the radioactive background into ac- 
count. 
The second comment deals with the use of 
butanol extraction to enrich modified nucle- 
otides relative to normal nucleotides. Since 
the great majority of nucleotides in treated 
DNA are not modified and adducted nucleo- 
tides account for only a small fraction of a 
percent of the total nucleotides available for 
labeling, either very large amounts of 32P 
must be used in labeling or some method is 
needed to reduce the amount of normal nu- 
cleotides available for labeling. Our proce- 
dure uses extraction of modified nucleotides 
into butanol at low pH and in the presence of 
a tetrabutylammonium phase transfer re- 
agent as described by Gupta (4). A different 
method involving nuclease PI digestion of 
normal nucleotides has been described by 
Reddy and Randerath (10). In theory this 
method hydrolyzes the 3’-phosphate from 
nucleotides, converting them to nucleosides 
which are no longer substrates for poly- 
nucleotide kinase. The adducted nucleotides 
are supposed to be resistant to this hydrolysis 
and can then be phosphorylated to the 32P- 
labeled 3’,5’-diphosphates. Since we were not 
successful in using this procedure with 2-AF 
adducts, we did not pursue its applicability to 
other carcinogen adducts. 
Another approach to solving the problem 
of minute amounts of DNA-carcinogen ad- 
ducts in the presence of larger amounts of 
normal nucleotides is used by Randerath et 
al. ( 11). According to this method, with limit- 
ing amounts of [T-~~P]ATP, adducted nucle- 
otides are labeled preferentially to normal 
nucleotides, achieving “adduct intensifica- 
tion.” The intensification is variable and 
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must be determined for each adduct by using 
the postlabeling under “normal” conditions, 
i.e., excess [T-~~P]ATP, and again under “in- 
tensification” conditions, i.e., [T-~~P]ATP be- 
ing the limiting reagent. 
HPLC analysis of 32P-postlabeled hepatic 
DNA from mice treated with 2-AF revealed 
two areas of radioactivity (Fig. 4). The area 
eluting in fractions 36, 37 and corresponding 
to dG-CSAAF accounted for 18% of the ad- 
duct radioactivity. The second area in frac- 
tions 40-42 represented the remaining 82% 
of adduct radioactivity. This distribution is 
very similar to the distribution reported for 
adducts in rat liver DNA of 15% dG-C8-AAF 
and 80% dG-C8-AF (8). 
Experiments comparing adduct formation 
in rapid and slow acetylator mice showed a 
threefold higher adduct load in hepatic DNA 
of rapid acetylators 3 h after exposure to 2- 
AF. The direction and magnitude of the 
difference between B6 and A mice are very 
similar to those found for in vitro liver aryl- 
amine N-acetyltransferase activity ( 12), 2-AF 
N-acetylation rates in primary hepatocyte 
cultures ( 13), and 2-AF elimination rates for 
intact mice (14). There is, therefore, a strong 
suggestion that rapid acetylator mice metabo- 
lize 2-AF more rapidly than slow acetylators 
and that among the metabolites formed are 
compounds that bind to hepatic DNA. 
The accuracy of quantitation of adducts by 
32P postlabeling p de ends on the efficiencies of 
several steps in the protocol. Incomplete hy- 
drolysis of purified DNA, incomplete extrac- 
tion of adducts into butanol, and less than 
100% reaction in the polynucleotide kinase 
step can result in a value for adduct forma- 
tion lower than the actual value. We have ex- 
amined this problem using 3H-labeled ami- 
nofluorene and benzo[a]pyrene adducts. For 
both compounds we compared the level of 
adducts determined by the 32P-postlabeling 
method with the level determined using 3H- 
labeled carcinogen and hydrolyzing, extract- 
ing, and phosphorylating as for unlabeled 
carcinogen except using nonradioactive 
ATP. The results indicated that the 32P value 
was 50 to 60% of the adducts determined by 
the tritium content of adducted DNA. Fur- 
thermore, we found that most of the losses 
occur in the butanol extraction step. Al- 
though Gupta (4) reports 79 to 99% efficiency 
for butanol extraction of aminofluorene ad- 
ducts formed by reaction of ultimate carcino- 
gens with DNA in vitro, we have not been 
able to duplicate such high values. The loss of 
adducts in the three steps mentioned above 
would be expected to occur whether the anal- 
ysis was carried out by HPLC or TLC. In 
TLC analysis additional losses may occur in 
cutting or scraping the TLC plates to recover 
adduct spots for counting. 
The adduct amounts we report have not 
been corrected for efficiency of extraction. In 
a comparison of adduct formation between 
strains or between tissues using the same car- 
cinogen, the efficiency of extraction is as- 
sumed to be almost constant. Thus, B6 mice 
accumulate three times the hepatic DNA ad- 
ducts of A mice whether one corrects for 
efficiency or not. Additional methods to im- 
prove the enrichment of adducts before post- 
labeling are under study. 
Although no general relationship between 
adduct structure and HPLC retention time is 
known at this time (other than the special sit- 
uation of the effect of an acetyl group on a 
particular adduct described above), a com- 
parison of the adduct peaks found by HPLC 
to adducts found by other methods is inter- 
esting and informative. 
Previously Lu et al. ( 15) used 32P postlabel- 
ing and TLC to examine adduct formation in 
mouse liver DNA after exposure to benzo[a]- 
pyrene and 4-aminobiphenyl. Two major 
benzo[a]pyrene adducts were detected, ac- 
counting for approximately 55 and 25% of 
adduct radioactivity. The radioactivity in the 
two benzo[a]pyrene adduct peaks detected 
by HPLC represents 67 and 33% of adduct 
radioactivity (Fig. 5A). 
For 4-aminobiphenyl, Lu et al. ( 15) found 
one major radioactive spot formed from 
mouse liver. Our results show a single peak 
preceded by a low plateau of radioactivity 
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(Fig. 5B). The nonacetylated dG-C&ABP ad- 
duct has been reported to account for at least 
80% of ABP adducts in rat liver ( 16). 
Our results for 2naphthylamine show a 
single adduct peak eluting at 42-43 min (Fig. 
5C). This position corresponds to the major 
adducts seen with 2-AF and 4-ABP. 2-NA has 
been reported to produce a dG-C8-2-NA ad- 
duct with dog liver DNA and dog urothelial 
DNA, as well as an N-ZdG and an N-6-deox- 
yadenosicyl adduct (17). Information on 
mouse hepatic DNA or adducts detected by 
32P postlabeling is lacking for 2-NA. 
Benzidine has been reported to produce 
only a single adduct with mouse hepatic 
DNA, N-(deoxyguanosin-8yl)-N-acetylben- 
zidine, one day after 7 days of oral adminis- 
tration ( 18). Reddy et al. (3) reported one ma- 
jor and two minor adducts from mouse skin 
DNA with benzidine. Our results show a ma- 
jor adduct and two or three minor peaks of 
radioactivity with mouse hepatic DNA (Fig. 
5D). The discrepancy between our results 
and those of Martin et al. (18) may be due to 
the increased sensitivity of 32P methods such 
as ours and that of Reddy et al. (3) compared 
to the use of ‘H labeled carcinogen by Martin 
et al. (18). Another possibility is suggested by 
the work of Kennelly et al. (19) who found 
at least one additional benzidine adduct in rat 
hepatic DNA treated in vitro. It was suggested 
that the additional adduct was not found in 
earlier experiments done in vivo because of 
the action of repair systems. Similarly one 
could speculate that in the 3-h exposure used 
here, repair mechanisms were not fully func- 
tional and additional adducts were found. 
Studies of adduct persistence would address 
this question. 
The alkenylbenzenes safrole and methyl- 
eugenol have been examined using 32P post- 
labeling by Lu et al. (15) and Randerath et 
al. (20). Lu found two major hepatic DNA 
adducts with safrole which were identified as 
dG adducts. The two adducts accounted for 
75 and 23% of adduct radioactivity. Our re- 
sults with safrole (Fig. 5E) show a single peak 
of radioactivity preceded by a low plateau of 
radioactivity. With methyleugenol, Rander- 
ath obtained an adduct map similar to that of 
safrole, with 87% of the radioactivity in a sin- 
gle spot. Our results with methyleugenol (Fig. 
5F) show a major adduct with one or two 
smaller earlier eluting peaks of radioactivity. 
The results of analysis of 32P-postlabeled 
DNA-aromatic carcinogen adducts obtained 
by us using HPLC and TLC results in the lit- 
erature, as discussed above, are, in general, 
similar. In some cases differences between the 
results reported here and results from other 
laboratories can probably be traced to differ- 
ences in dosage, method of administration, 
species or strain of animal, and length of ex- 
posure to the carcinogen. Some of the differ- 
ences in detail are also likely due to differ- 
ences in the type of separation used: ion ex- 
change for TLC and reverse phase for HPLC. 
Also, the HPLC method is separating larger 
molecules than the TLC method in that 
for HPLC the covalent dG-carcinogen ad- 
duct also contains tetrabutylammonium ions 
bound to phosphates. 
While the TLC method often produces 
more areas of radioactivity on the chromato- 
gram which may indicate resolution of minor 
adducts, the HPLC method is more rapid and 
less tedious to perform. As a rapid screening 
method to detect adduct formation, the 
HPLC procedure has been shown to be effec- 
tive in detecting adducts formed by a variety 
of aromatic carcinogens. We have also shown 
the value of HPLC analysis in determining 
formation of specific adducts and the useful- 
ness of the method in measuring differences 
in DNA damage caused by genetically deter- 
mined variations in metabolic pathways. 
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